Skip to main content
. 2016 Apr 12;8(29):46801–46817. doi: 10.18632/oncotarget.8695

Figure 6. The combination of SC-2001 and ABT-737 inhibited the MIC-mediated tumor formation in vivo.

Figure 6

The treatment effects were tested in a xenograft model initiated with a low-number of MIC-enriched cells. For tumor injection, we used the surviving cells from the sphere cultures, upon treatments of SC-2001 and ABT-737, either alone or in combination, at the density of 50,000 viable cells per injection. A. Tumor-free survival curve shows a significantly longer tumor–free time in the combination group, compared to the vehicle or single drug group (P<0. 001). B. The percentage of tumor incidence was significantly lower in the combination group compared to control or single drug groups (P<0.05). C. Sphere assays with the tumor cells collected at the end of the animal experiment, and the number of spheres was significantly lower in the combination group compared to control or single drug groups (P< 0.001). N=3. ***indicates P<0.001 or less; *indicates P<0.05.